Advisory Board to guide Infinity Bio's research strategy, driving innovation in disease diagnostics and therapeutic advancements.
Read More
Resources
News
Stay current with our recent news, updates, and announcements.
Infinity Bio is proud to announce that we’ve been awarded a prestigious Gold MarCom Award for our website. This recognition highlights our commitment to not only advancing scientific innovation but also ensuring that our digital presence reflects the cutting-edge work we do in antibody profiling. Our newly designed website was crafted to enhance the user experience, making it easier for our visitors to explore our mission and innovations. We’re honored to be recognized by MarCom for excellence in web design and communication.
Read More
New service leverages proprietary technology to provide unprecedented insights into antibody autoreactivity for translational research and therapeutic development.
Read More
Infinity Bio, Inc. is proud to announce its selection by the TEDDY (The Environmental Determinants of Diabetes in the Young) study to provide comprehensive antibody reactome services for their large cohort. This collaboration marks a significant milestone for Infinity Bio as it continues to advance its mission to deliver cutting-edge immunological insights and solutions.
Read More
Infinity Bio, Inc., a biotechnology company specializing in antibody reactome profiling, hosted a special community event aimed at engaging and inspiring Baltimore children with an interest in STEM. The event took place on July 22, 2024, at Infinity Bio’s office and laboratory at 6200 Seaforth Street, Baltimore, MD, and featured various activities designed to spark interest in science and technology.
Read More
Infinity Bio, a technology company known for its innovative antibody reactome profiling service, will host an open house event at its state-of-the-art laboratory at 6200 Seaforth Street in Baltimore on July 23, 2024. This event is designed to give members of the local scientific and biotech community an exclusive look at the research and technologies that are driving developments in immunology.
Read More
Infinity Bio takes a business-to-business approach to pharmaceuticals. Here's more on the company and its growth.
Read More
Infinity Bio, Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. This platform offers unparalleled depth in immune system analysis, advancing immunology, virology, autoimmunity, and allergy research, providing new disease insights, and discovering new biomarkers and treatments. The MIPSA technology exploits recent advances in high throughput DNA sequencing and DNA synthesis, to create and analyze the most complete panels of immune targets available.
Read More